Long-term use of lucerastat may protect kidneys in Fabry: Trial data
Long-term dosing with lucerastat, an experimental substrate reduction treatment from Idorsia, may slow the loss of kidney function in adults...
Long-term dosing with lucerastat, an experimental substrate reduction treatment from Idorsia, may slow the loss of kidney function in adults...
BioMed X, a Heidelberg, Germany-based innovation hub for pharma, launched its first research project in partnership with the Government of...
Large-scale UK Biobank data show that the EAT-Lancet planetary health diet is associated with lower CKD risk, with genetics, green...
It is hard not to feel a certain sadness reading arguments for legalising the sale of kidneys that rely more...
Credit: CIPhotos/Getty Images Researchers at Mayo Clinic have developed a base editing therapy for autosomal dominant polycystic kidney disease (ADPKD),...
A single-dose gene-editing therapy has shown it can correct the genetic cause of autosomal dominant polycystic kidney disease in preclinical...